Aridis Pharmaceuticals (ARDS)
(Delayed Data from OTC)
$0.00 USD
0.00 (0.00%)
Updated Sep 5, 2024 02:38 PM ET
NA Value
NA Growth NA Momentum NA VGMFundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
ARDS 0.00 0.00(0.00%)
Will ARDS be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for ARDS based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for ARDS
Avid Bioservices (CDMO) Reports Q2 Loss, Lags Revenue Estimates
Aridis (ARDS) Up on Receiving FDA's QIDP Designation for AR-301
ARDS: What are Zacks experts saying now?
Zacks Private Portfolio Services
Aridis (ARDS) Up on Regulatory Update for Pneumonia Drug
Aridis (ARDS) Up After FDA Nod for Pneumonia Drug Study Design
Biotech Stock Roundup: ACAD's Drug Approval, SGEN to be Acquired by PFE & More
Other News for ARDS
Aridis Provides Corporate Update